Article 16 - The Endocannabinoid System: What It Is and Why It Matters

The endocannabinoid system is one reason cannabis-based medicines cannot be understood through a single number on a label.

It is a biological signalling system found throughout the body. It interacts with naturally produced compounds, receptors, and enzymes, and it may influence several processes involved in normal physiology. Cannabis-based medicines can interact with this system, but the effects are complex and vary between products and patients.

What is the endocannabinoid system?

The endocannabinoid system, often shortened to ECS, is a network involved in cell-to-cell signalling. It includes endocannabinoids made by the body, cannabinoid receptors, and enzymes that help produce, transport, and break down signalling molecules.

Research has linked the system to processes including pain signalling, appetite, mood, sleep, memory, movement, and immune activity. That does not mean the ECS controls each process on its own. These processes involve many biological systems working together.

The ECS is also not a single switch that can simply be turned up or down. Its activity changes across tissues and circumstances, and its clinical significance is still being studied.

The main parts of the system

Endocannabinoids

Endocannabinoids are signalling molecules produced by the body. Two commonly discussed examples are anandamide and 2-AG. They are made when needed and are then broken down by enzymes.

Endocannabinoids are not the same thing as the cannabinoids found in the cannabis plant. The plant compounds are often called phytocannabinoids. The names are related because both can interact with cannabinoid signalling, but they are not interchangeable.

Receptors

Cannabinoid receptors are proteins found in different parts of the body. CB1 receptors are widely distributed in the nervous system and are also found elsewhere. CB2 receptors are associated particularly with immune tissues, although both receptor types have broader roles than a simple body-location description suggests.

Other receptors and biological pathways may also be involved. This is one reason why a product containing several compounds can produce effects that are not explained by one receptor alone.

Enzymes

Enzymes help make and break down endocannabinoids. The timing and location of these processes matter. A signal that is produced briefly in one tissue should not be treated as equivalent to a continuously active signal throughout the body.

How plant cannabinoids fit into the picture

THC and CBD are the best-known plant cannabinoids, but cannabis contains many others. They can interact with the body in different ways and may influence more than one biological pathway.

THC is associated with effects that can include changes in perception, mood, coordination, alertness, and memory. CBD has a different pharmacology and does not simply produce the same effects at a lower intensity. The response to either compound depends on dose, route, formulation, patient factors, and the presence of other medicines or substances.

A product label tells you about composition. It does not predict exactly how your own ECS, nervous system, or wider physiology will respond.

What does “balance” mean?

The phrase “ECS balance” is often used in public discussions. It can be a useful way to introduce the idea of regulation, but it should not be treated as a diagnosis.

There is no general consumer test that can tell a patient that their endocannabinoid system is deficient and then calculate a correct cannabis dose. Claims that a product can restore a precisely defined balance should be treated cautiously unless they are supported by appropriate evidence.

Medical treatment is not based on chasing a theoretical ideal. It is based on the patient's symptoms, history, prescribed product, response, unwanted effects, and clinical review.

Why the same product affects people differently

Two patients can use products with similar labelled cannabinoid percentages and experience different effects. Relevant factors may include:

• Age, body composition, metabolism, and general health
• Previous exposure and tolerance
• Route of administration and delivery method
• Food, sleep, stress, and daily routine
• Other medicines, supplements, or substances
• Underlying conditions and treatment goals
• Product formulation, batch, and storage

This is why another patient's dose, experience, or product preference cannot be used as a personal prescription.

What the ECS does not prove

The existence of the endocannabinoid system does not prove that every cannabis product will be beneficial, that a whole-plant product is always superior, or that a higher cannabinoid number will produce a better outcome.

It also does not remove the need for diagnosis, monitoring, medication review, or professional advice. A plausible biological mechanism is not the same as clinical evidence for a particular product or condition.

Questions patients can ask

If your clinician has prescribed a cannabis-based medicine, useful questions may include:

• What is the treatment intended to help me monitor?
• What response would suggest that the plan is helping?
• What unwanted effects should I record?
• Could my other medicines affect the response?
• How will changes in product, batch, route, or dose be reviewed?
• When should I contact the prescribing team?

Keep the discussion focused on your medicine and your response. General claims about the ECS should not replace a review of your individual treatment.

The honest conclusion

The endocannabinoid system is a real and important area of biological research. It helps explain why cannabinoids can influence several systems in the body and why the effects of cannabis-based medicines can be complex.

It is not a simple explanation for every symptom and it is not a shortcut to choosing a product or dose. The responsible approach is to treat the ECS as part of the science, then assess treatment through evidence, careful observation, clinical supervision, and honest communication.

Sources and further reading

This article is general patient education and does not diagnose an endocannabinoid disorder or recommend a treatment. For advice about a prescribed medicine, speak with your prescribing clinician or pharmacist.